Literature DB >> 31737508

Immunotherapy in EGFR mutant non-small cell lung cancer: when, who and how?

Debora Bruno1, Afshin Dowlati1.   

Abstract

Entities:  

Year:  2019        PMID： 31737508      PMCID： PMC6835106          DOI： 10.21037/tlcr.2019.06.02

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  22 in total

1.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

Authors:  Achim Rittmeyer; Fabrice Barlesi; Daniel Waterkamp; Keunchil Park; Fortunato Ciardiello; Joachim von Pawel; Shirish M Gadgeel; Toyoaki Hida; Dariusz M Kowalski; Manuel Cobo Dols; Diego L Cortinovis; Joseph Leach; Jonathan Polikoff; Carlos Barrios; Fairooz Kabbinavar; Osvaldo Arén Frontera; Filippo De Marinis; Hande Turna; Jong-Seok Lee; Marcus Ballinger; Marcin Kowanetz; Pei He; Daniel S Chen; Alan Sandler; David R Gandara
Journal:  Lancet       Date:  2016-12-13       Impact factor: 79.321

2.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Authors:  Roy S Herbst; Paul Baas; Dong-Wan Kim; Enriqueta Felip; José L Pérez-Gracia; Ji-Youn Han; Julian Molina; Joo-Hang Kim; Catherine Dubos Arvis; Myung-Ju Ahn; Margarita Majem; Mary J Fidler; Gilberto de Castro; Marcelo Garrido; Gregory M Lubiniecki; Yue Shentu; Ellie Im; Marisa Dolled-Filhart; Edward B Garon
Journal:  Lancet       Date:  2015-12-19       Impact factor: 79.321

3.  A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.

Authors:  A Lisberg; A Cummings; J W Goldman; K Bornazyan; N Reese; T Wang; P Coluzzi; B Ledezma; M Mendenhall; J Hunt; B Wolf; B Jones; J Madrigal; J Horton; M Spiegel; J Carroll; J Gukasyan; T Williams; L Sauer; C Wells; A Hardy; P Linares; C Lim; L Ma; C Adame; Edward B Garon
Journal:  J Thorac Oncol       Date:  2018-06-01       Impact factor: 15.609

4.  Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation.

Authors:  James Chih-Hsin Yang; Shirish M Gadgeel; Lecia VanDam Sequist; Chien-Liang Wu; Vassiliki A Papadimitrakopoulou; Wu-Chou Su; Joseph Fiore; Sanatan Saraf; Harry Raftopoulos; Amita Patnaik
Journal:  J Thorac Oncol       Date:  2018-12-04       Impact factor: 15.609

5.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

6.  EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.

Authors:  Justin F Gainor; Alice T Shaw; Lecia V Sequist; Xiujun Fu; Christopher G Azzoli; Zofia Piotrowska; Tiffany G Huynh; Ling Zhao; Linnea Fulton; Katherine R Schultz; Emily Howe; Anna F Farago; Ryan J Sullivan; James R Stone; Subba Digumarthy; Teresa Moran; Aaron N Hata; Yukako Yagi; Beow Y Yeap; Jeffrey A Engelman; Mari Mino-Kenudson
Journal:  Clin Cancer Res       Date:  2016-05-25       Impact factor: 12.531

7.  Impact of gefitinib in early stage treatment on circulating cytokines and lymphocytes for patients with advanced non-small cell lung cancer.

Authors:  Jin Sheng; Wenfeng Fang; Xia Liu; Shan Xing; Jianhua Zhan; Yuxiang Ma; Yan Huang; Ningning Zhou; Hongyun Zhao; Li Zhang
Journal:  Onco Targets Ther       Date:  2017-02-21       Impact factor: 4.147

8.  Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

Authors:  Mark A Socinski; Robert M Jotte; Federico Cappuzzo; Francisco Orlandi; Daniil Stroyakovskiy; Naoyuki Nogami; Delvys Rodríguez-Abreu; Denis Moro-Sibilot; Christian A Thomas; Fabrice Barlesi; Gene Finley; Claudia Kelsch; Anthony Lee; Shelley Coleman; Yu Deng; Yijing Shen; Marcin Kowanetz; Ariel Lopez-Chavez; Alan Sandler; Martin Reck
Journal:  N Engl J Med       Date:  2018-06-04       Impact factor: 91.245

9.  PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis.

Authors:  Minghui Zhang; Guoliang Li; Yanbo Wang; Yan Wang; Shu Zhao; Pu Haihong; Hongli Zhao; Yan Wang
Journal:  Sci Rep       Date:  2017-08-31       Impact factor: 4.379

10.  Association between PD-L1 expression and driver gene status in non-small-cell lung cancer: a meta-analysis.

Authors:  Bo Lan; Chengxi Ma; Chengyan Zhang; Shoujie Chai; Pingli Wang; Liren Ding; Kai Wang
Journal:  Oncotarget       Date:  2018-01-05
View more
  7 in total

1.  Targeting the ERβ/HER Oncogenic Network in KRAS Mutant Lung Cancer Modulates the Tumor Microenvironment and Is Synergistic with Sequential Immunotherapy.

Authors:  Abdulaziz A Almotlak; Mariya Farooqui; Adam C Soloff; Jill M Siegfried; Laura P Stabile
Journal:  Int J Mol Sci       Date:  2021-12-22       Impact factor: 5.923

2.  Liquid Biopsy Testing for the Management of Patient with Non-Small Cell Lung Cancer Carrying a Rare Exon-20 EGFR Insertion.

Authors:  Alessandro Morabito; Anna Manzo; Agnese Montanino; Anna Maria Rachiglio; Vincenzo Sforza; Raffaella Pasquale; Raffaele Costanzo; Monica R Maiello; Claudia Sandomenico; Marianna Gallo; Giuliano Palumbo; Antonella De Luca; Antonello La Rocca; Nicola Martucci; Rossella De Cecio; Carmine Picone; Secondo Lastoria; Nicola Normanno
Journal:  Oncologist       Date:  2022-02-03

Review 3.  EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment.

Authors:  Clelia Madeddu; Clelia Donisi; Nicole Liscia; Eleonora Lai; Mario Scartozzi; Antonio Macciò
Journal:  Int J Mol Sci       Date:  2022-06-10       Impact factor: 6.208

4.  Molecular Characteristics and the Effect of KRAS Mutation on the Prognosis of Immunotherapy in Non-Small Cell Lung Cancer in Xinjiang, China.

Authors:  Guomin Gu; Bo Yu; Hua Wan; Suqiong Lu; Xiaodan Zhu; Yan Zhao; Yujing Fuxi; Chunling Liu
Journal:  Onco Targets Ther       Date:  2022-09-21       Impact factor: 4.345

Review 5.  Immunotherapy in oncogene addicted non-small cell lung cancer.

Authors:  Luke McLean; Jose Luis Leal; Benjamin J Solomon; Thomas John
Journal:  Transl Lung Cancer Res       Date:  2021-06

6.  Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy.

Authors:  Marco Cefalì; Samantha Epistolio; Giulia Ramelli; Dylan Mangan; Francesca Molinari; Vittoria Martin; Stefania Freguia; Luca Mazzucchelli; Patrizia Froesch; Milo Frattini; Luciano Wannesson
Journal:  J Clin Med       Date:  2022-03-15       Impact factor: 4.241

7.  Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA.

Authors:  Masahiro Tsuboi; Walter Weder; Carles Escriu; Collin Blakely; Jianxing He; Sanja Dacic; Yasushi Yatabe; Lingmin Zeng; Andrew Walding; Jamie E Chaft
Journal:  Future Oncol       Date:  2021-07-19       Impact factor: 3.404
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.